コンパス・セラピューティクス
Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.13 | $0 | -$14M |
| 2026 Q1 | -0.10 | $0 | -$17M |
| 2025 Q4 | -0.09 | $0 | -$13M |
| 2025 Q3 | -0.10 | $0 | -$11M |
| 2025 Q2 | -0.14 | $0 | -$12M |
| 2025 Q1 | -0.12 | $0 | -$13M |
| 2024 Q4 |
| -0.11 |
| $0 |
| -$9M |
| 2024 Q3 | -0.08 | $0 | -$11M |